Globus Medical, Inc.
GMEDNYSEHealthcare● Active
$80.00
+$0.00(+0.00%)
Market Cap$10.8B
P/E Ratio—
52W High$101.4
52W Low$51.79
Globus Medical, Inc. (GMED) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GMED · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$1.12
Est. $0.92 · +21.7%
Revenue
$0.76B
Est. $0.74B · +2.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
GMED reports quarterly as a NYSE-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.00
Rev. $0.01B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.00
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $1.12 | — | — | — | $0.78B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.92 | $1.12 | +21.7% | $0.76B | $0.74B | +2.6% |
| ▲ Q1 FY2026 | Feb 24, 2026 | $1.06 | $1.28 | +20.8% | $0.83B | $0.80B | +3.1% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.78 | $1.18 | +51.1% | $0.77B | $0.73B | +4.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.76 | $0.86 | +13.2% | $0.75B | $0.74B | +0.3% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.74 | $0.68 | -8.6% | $0.60B | $0.63B | -4.4% |
| ▲ Q1 FY2025 | Feb 20, 2025 | $0.74 | $0.84 | +13.5% | $0.66B | $0.65B | +1.8% |
| ▲ Q4 FY2024 | Nov 5, 2024 | $0.65 | $0.83 | +28.3% | $0.63B | $0.60B | +3.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$1.12
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$1.12
EPS Est.
$0.92
EPS Surpr.
+21.7%
Revenue
$0.76B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$1.28
EPS Est.
$1.06
EPS Surpr.
+20.8%
Revenue
$0.83B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$1.18
EPS Est.
$0.78
EPS Surpr.
+51.1%
Revenue
$0.77B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.86
EPS Est.
$0.76
EPS Surpr.
+13.2%
Revenue
$0.75B
Q2 FY2025
May 8, 2025Miss
EPS Actual
$0.68
EPS Est.
$0.74
EPS Surpr.
-8.6%
Revenue
$0.60B
Q1 FY2025
Feb 20, 2025Beat
EPS Actual
$0.84
EPS Est.
$0.74
EPS Surpr.
+13.5%
Revenue
$0.66B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
$0.83
EPS Est.
$0.65
EPS Surpr.
+28.3%
Revenue
$0.63B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.52 | $1.54 | $1.56 | 7 |
| Q3 FY2028 | $1.39 | $1.42 | $1.43 | 4 |
| Q2 FY2028 | $1.32 | $1.34 | $1.36 | 6 |
| Q1 FY2028 | $1.25 | $1.27 | $1.29 | 4 |
| Q4 FY2027 | $1.41 | $1.43 | $1.45 | 6 |
| Q3 FY2027 | $1.25 | $1.27 | $1.29 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.9B | $1.0B | $1.0B | 6 |
| Q3 FY2028 | $0.9B | $0.9B | $0.9B | 3 |
| Q2 FY2028 | $0.9B | $0.9B | $0.9B | 5 |
| Q1 FY2028 | $0.8B | $0.9B | $0.9B | 3 |
| Q4 FY2027 | $0.9B | $0.9B | $0.9B | 7 |
| Q3 FY2027 | $0.8B | $0.9B | $0.9B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +21.7% | $89.22 | $85.07 | -4.65% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +20.8% | $93.40 | $91.88 | -1.63% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +51.1% | $61.51 | $61.71 | +0.33% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +13.2% | $52.83 | $54.07 | +2.35% |
| ▼ Q2 FY2025 | May 8, 2025 | -8.6% | $71.51 | $72.46 | +1.33% |
| ▲ Q1 FY2025 | Feb 20, 2025 | +13.5% | $84.09 | $84.12 | +0.04% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +28.3% | $74.72 | $75.58 | +1.15% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +10.3% | $67.80 | $69.05 | +1.84% |
Q2 FY2026-4.65%
Report Date
May 7, 2026
EPS Beat/Miss
+21.7%
Price Before
$89.22
Price After
$85.07
Q1 FY2026-1.63%
Report Date
Feb 24, 2026
EPS Beat/Miss
+20.8%
Price Before
$93.40
Price After
$91.88
Q4 FY2025+0.33%
Report Date
Nov 6, 2025
EPS Beat/Miss
+51.1%
Price Before
$61.51
Price After
$61.71
Q3 FY2025+2.35%
Report Date
Aug 7, 2025
EPS Beat/Miss
+13.2%
Price Before
$52.83
Price After
$54.07
Q2 FY2025+1.33%
Report Date
May 8, 2025
EPS Beat/Miss
-8.6%
Price Before
$71.51
Price After
$72.46
Q1 FY2025+0.04%
Report Date
Feb 20, 2025
EPS Beat/Miss
+13.5%
Price Before
$84.09
Price After
$84.12
Q4 FY2024+1.15%
Report Date
Nov 5, 2024
EPS Beat/Miss
+28.3%
Price Before
$74.72
Price After
$75.58
Q3 FY2024+1.84%
Report Date
Aug 6, 2024
EPS Beat/Miss
+10.3%
Price Before
$67.80
Price After
$69.05
Avg Beat Reaction-0.08%
Avg Miss Reaction+1.33%
Beat Rate7 / 8 quarters
Largest Move-4.65% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GMED ends December
Globus Medical, Inc. (GMED) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $1.12 — beating the analyst consensus of $0.92 by +21.7%. GMED has beaten EPS estimates for 4 consecutive quarters. The next GMED earnings date is expected around September 1, 2026.
Each quarter, investors track GMED earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GMED revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GMED's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GMED earnings · 5 questionsGlobus Medical, Inc.'s next earnings report is expected around September 1, 2026. GMED typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GMED historically reports after market close (AMC).
GMED earnings datewhen is GMED earningsGMED next earnings datewhen does GMED report earningsGMED earnings calendar
▸ Source: FMP · Globus Medical, Inc. SEC filings · US GAAP · Globus Medical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026